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Aims Although stimulation with sphingosylphosphorylcholine (SPC) or sphingosine-1-phosphate (S1P)
generally leads to similar vascular responses, the contractile patterns and their underlying signalling
mechanisms are often distinct. We investigated the different reliance upon Ca2þ-dependent and
Ca2þ-sensitizing mechanisms of constriction in response to SPC or S1P in coronary arteries.
Methods and results Contractile responses, changes in [Ca2þ]i, and phosphorylation of myosin light
chain phosphatase-targeting subunit (MYPT1) were measured. SPC induced a concentration-dependent
sustained contraction. S1P evoked a rapid rise in force (initial transient), which was followed by a sec-
ondary sustained force. In the absence of extracellular Ca2þ, the concentration dependency of constric-
tion to SPC was shifted to the right, but with no change in maximum force, whereas S1P-induced
contraction was significantly blunted. Cyclopiazonic acid (CPA) significantly decreased the initial tran-
sient force induced by S1P. In isolated single cells, S1P markedly increased [Ca2þ]i, whereas only a
modest elevation was noted with SPC. The S1P-induced elevation of [Ca2þ]i was abolished by pre-treat-
ment with CPA and was significantly reduced in the absence of extracellular Ca2þ. In b-escin-permeabi-
lized strips, SPC augmented pCa 6.3-induced force; this was significantly inhibited by fasudil
hydrochloride. S1P induced little or no augmentation of pCa 6.3-induced force. In intact arteries,
SPC-induced contraction was completely inhibited by fasudil hydrochloride. Fasudil hydrochloride had
no effect on the initial transient force induced by S1P but significantly inhibited the secondary sustained
force. SPC induced a several-fold increase in Thr696 and Thr853 phosphorylation of MYPT1, but S1P did
not affect phosphorylation of MYPT1.
Conclusion Our results suggest that constriction of coronary arteries in response to the bioactive lipid
S1P or SPC occurs by distinct signalling pathways. Activation of the RhoA/RhoA-associated kinase
pathway and subsequent phosphorylation of MYPT1 play a key role in SPC-induced coronary contraction,
whereas elevation of [Ca2þ]i is crucial for S1P-induced coronary constriction.
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1. Introduction
The biologically active sphingomyelin metabolites, sphingo-
sylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P),
sphingosine, and ceramide are generated upon cell acti-
vation from membrane phospholipids as parts of the sphin-
gomyelin cycle.1,2 They are present in plasma at high
nanomolar concentrations, released from activated plate-
lets,3,4 and increased in inflammation and atherosclerosis.5
The sphingomyelin pathway is emerging as an important reg-
ulator of membrane signal transduction and a variety of cel-
lular functions.6,7 In particular, SPC and S1P have recently
been added to the list of vascular modulators.8–11
Numerous studies have confirmed a modulation of vascu-
lar tone by SPC and S1P, but have yielded equivocal results.
Several investigators have reported vasoconstriction
responses for SPC and S1P,12–15 whereas other studies
have found the opposite.16–19 The mechanisms involved in
SPC- and S1P-induced contractions also have not been
fully identified. Recently, evidence for the involvement
of the elevation of intracellular free Ca2þ concentration
([Ca2þ]i)
20 and Ca2þ-sensitization mechanisms, especially
phosphorylation of myosin light chain phosphatase
(MLCP)-targeting subunit (MYPT1) by RhoA/RhoA-
associated kinase (ROCK) pathway,15,16,21–23 was reported
from several investigations. Taken together, these results
suggest that the degree and/or type of vascular response
to SPC or S1P differs between vessel types, particularly
with respect to the vessel size, involvement of
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endothelium, and different expression patterns of their
receptors.10
Vasospasm is a sustained abnormal contraction of the
artery.24–26 Several spasmogenic substances have been
suggested. These include oxyhaemoglobin, endothelin-1,
thrombin, serotonin, noradrenalin, and thromboxane.27–29
Sphingolipids have been suggested as candidates of spasmo-
genic substances because they are released from activated
platelets and increase in inflammation, predisposing situ-
ations for vasospasm. The cause and pathophysiology of
vasospasm have been intensively investigated but not fully
understood. Recent investigations suggested that Ca2þ-
sensitization mechanisms, especially PKC and RhoA/ROCK
pathways, are involved in vasospasm rather than increase
in [Ca2þ]i.
21,27,30,31 To determine whether sphingolipids
operate as spasmogenic substances, and whether different
sphingolipids exert different potencies, studies to compare
the patterns and specific mechanisms between SPC- and
S1P-induced contractions in the same artery are needed.
In this study, we investigated the differences in patterns
between SPC- and S1P-induced contractions in rabbit coron-
ary arteries by measuring contractile responses. We also
investigated underlying mechanisms involved in SPC- and
S1P-induced contractions by measuring contractile
responses in normal and permeabilized strips, changes in
[Ca2þ]i, and phosphorylation of MYPT1.
2. Methods
This investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996). All procedures were per-
formed in accordance with protocols approved by the Institutional
Animal Care and Use Committee.
2.1 Organ bath study
New Zealand white rabbits weighing 1.7–2.2 kg were anaesthetized
with pentobarbital sodium (50 mg/kg) containing anticoagulant,
heparin (2000 IU/kg). The heart was excised and placed in a modi-
fied Krebs–Henseleit (KH) solution composed of (in mM): NaCl,
119; KCl, 4.6; CaCl2, 2.5; KH2PO4, 1.2; NaHCO3, 25; MgSO4 1.5;
glucose 11. The KH solution was continuously aerated with a
mixture of 95% O2 and 5% CO2. The second branch of left descending
coronary arteries was dissected out from the heart and ring seg-
ments were prepared (4–5 mm in length). To avoid the possible
influences of endothelium-derived factors, the endothelium of the
arterial ring was removed by gently rubbing the endothelial
surface with forceps. Removal of endothelium was confirmed by
observing the absence of relaxation on challenge with acetylcholine
when 70 mM Kþ solution (equimolar substitution of Naþ with Kþ)-
induced contraction had reached plateau.
Force was measured as described previously.32 Briefly, arterial
rings were held horizontally in a temperature-controlled, 15 mL
organ chamber. The KH solution was maintained at 378C and was
continuously aerated with 95% O2 and 5% CO2. One end of the arter-
ial ring was anchored to a stationary support and the other end was
connected to a force-displacement transducer to monitor the
muscle contraction. Muscle strips were stretched passively by
imposing an optimal resting force of 5 mN (which was evaluated
as maximum tension developed by 70 mM Kþ solution), which was
maintained throughout the experiment. Each preparation was equi-
librated for more than 60 min before starting the experiment. In
some preparations, force measurements were recorded in the
absence of external Ca2þ (0Ca2þ-1 mM EGTA solution). The
0Ca2þ-1 mM EGTA solution was prepared by omission of Ca2þ from
KH solution and addition of 1 mM EGTA. Care was taken to ensure
the pH remained buffered to 7.3.
SPC or S1P was added cumulatively to construct concentration–
response curves. Incubation time of each concentration for SPC
and S1P was 20 min and 15 min, respectively. A maximal concen-
tration of SPC (5 mM) or S1P (15 mM) was selected for further
force experiments. In Ca2þ-imaging experiments, 5 mM SPC or
1 mM S1P was selected. The effects of several pharmacological
inhibitory agents were examined following a 30 min pre-incubation
period and continued exposure thereafter to the drug during the
application of SPC or S1P.
2.2 Single-cell isolation and Ca21 imaging
Single smooth muscle cells were enzymatically isolated from the
rabbit coronary arteries. After coronary artery was isolated from
the heart, it was moved to a Ca2þ-free Tyrode’s solution (0Ca2þ
PSS) of following composition (in mM): NaCl, 140; KCl, 5.4; MgCl2,
1.0; HEPES, 10; glucose, 5.5; pH was adjusted to 7.4 with NaOH.
At first, the vessel was incubated in 0Ca2þ PSS for 15 min at 378C.
Secondly, it was incubated in 0Ca2þ PSS with collagenase (2 mg/
mL, 190 U; Wako, Richmond, VA, USA), papain (0.0165 mg/mL,
Sigma, St Louis, MO, USA), dithiothreitol (0.165 mg/mL, Sigma),
trypsin inhibitor (2 mg/mL, Sigma) for 60 min at 378C. After enzy-
matic digestion, segments were transferred to 0Ca2þ PSS and
single cells were dispersed by gentle agitation with glass pipette.
Isolated single cells were stored in 1 mM Ca2þ Tyrode’s solution at
48C until use.
Changes in [Ca2þ]i were measured in isolated single cells loaded
with the Ca2þ-sensitive dye fura-2/AM (Molecular Probes, Eugene,
OR, USA) using a dual excitation digital Ca2þ-imaging system (Till
Photonics, Munich, Germany) equipped with an intensified CCD
camera (Roper Scientific, Tucson, AZ, USA). The imaging system
was mounted on an inverted microscope (Olympus, Tokyo, Japan).
The strips of rabbit coronary arteries were loaded with 1 mM
fura-2/AM in Tyrode’s solution for 30 min at room temperature.
Cells were illuminated with a xenon arc lamp at 340 and 380 nm
and emitted light collected at 510 nm with a CCD camera from
regions that encompassed single cells. The ratio of F340 to F380
[R(F340/F380)] was calculated as an indicator of [Ca
2þ]i. The absolute
Ca2þ concentration was not calculated in this experiment because
the dissociation constant of fluorescence indicator for Ca2þ in
cytosol may be different from that obtained in vitro.
2.3 Permeabilization with b-escin and force
recording
Force in permeabilized strips was measured as described pre-
viously.33 Briefly, thin strips (200 mm wide and 2–3 mm long) of
coronary artery were dissected and stretched to a resting force
of 5 mN. Strips were incubated in relaxing solution containing
4.5 mM MgATP, 1 mM EGTA, 2 mM magnesium methanesulfonate,
74.1 mM potassium methanesulfonate, 30 mM piperazine-N,
N-bis[2-ethanesulfonic acid] (PIPES), 10 mM creatine phosphate
neutralized to pH 7.1 with KOH at 208C for 20 min. Cell permeabili-
zation was achieved by incubation at room temperature (208C) in
b-escin (30 mM, Sigma) in the relaxing solution for 25 min. In the
pCa solution, 10 mM EGTA was used to give a desired concentration
of free Ca2þ. Ionic strength was constant at 0.2 M by adjusting the
concentration of potassium methanesulfonate. The SPC- or
S1P-induced contraction was examined at pCa 6.3 including 10 mM
of GTPgS (Sigma).
2.4 Western blot
Phosphorylation of the total MYPT, p(696)MYPT, and p(853)MYPTwas
measured by using western blot. After SPC- and S1P-induced tension
was stable, the vessels were immediately frozen by immersion in
liquid nitrogen. For each preparation, vessels from 20 animals
were pooled. Protein-matched samples (40 mg protein/lane) were
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subjected to electrophoresis on 7.5% SDS–polyacrylamide gels and
then transferred to nitrocellulose membranes. Reversible Ponceau
S staining of the membranes was performed to confirm the equal
loading of protein. Membranes were incubated in 5% skim milk in
PBS-Tween buffer for 2 h at room temperature and then were incu-
bated overnight at 48C in the presence of primary antibodies to
MYPT-total (1:500; BD Bioscience, San Jose, CA, USA: Cat No.
612164), MYPT-696 (1:500; Upstate, Charlottesville, VA, USA: Cat
No. 07-251), MYPT-853 (1:500; Upstate; Cat No. 36-003). Membranes
were washed and then incubated with horseradish peroxidase-
conjugated secondary antibody (1:10 000; Calbiochem, Darmstadt,
Germany) for 1 h at room temperature. Immunoreactive bands
were visualized by enhanced chemiluminescence (ECL; Amersham,
Uppsala, Sweden). Developed films from ECL were scanned, and
MYPT phosphorylation was quantitated by densitometry of X-ray
films using Fuji Photo Film Image with Fuji film image gauge
program (ver 2.54; Fuji Photo Film Co, Tokyo, Japan). Care was
taken to avoid saturation of the signal at any step in the process.
2.5 Drugs and chemicals
The following drugs were used: S1P (Sigma), SPC (Sigma), cyclopia-
zonic acid (CPA; TOCRIS, Ellisville, MO, USA), and fasudil hydrochlo-
ride (TOCRIS). General laboratory reagents used were of analytical
grade or better. S1P was dissolved in 100% methanol. SPC was dis-
solved in 100% ethanol.
2.6 Statistics
All values given in the text are mean+ SEM and were analysed by
ANOVA, followed by Tukey’s test. Significant differences were
taken at the P , 0.05 level. Force was expressed as a relative per-
centage of the amplitude of the 70 mM Kþ solution in organ bath
study, 50.5 mM Kþ solution in Ca2þ imaging, and pCa 4.5 in
permeabilization study, respectively. New strips of coronary artery
were used for each separate experiment.
3. Results
3.1 SPC- and S1P-induced contractions in rabbit
coronary artery
SPC (5 mM) induced a sustained contraction in rabbit coron-
ary arteries, which reached a maximum plateau level within
10 min (Figure 1, inset of A1). SPC-induced contraction was
maintained for at least 1 h. As shown in Figure 1A, the
SPC-induced contraction was concentration-dependent.
The maximum response was obtained at 5 mM. The magni-
tude of the 5 mM SPC-induced contraction was 101.81+
5.92% (n ¼ 6) of the contraction produced by 70 mM Kþ sol-
ution. We also tested the effect of the same volume of
vehicle (ethanol) used at 30 mM SPC on the resting and
70 mM Kþ solution-induced contraction. Treatment with
vehicle had no effect (data not shown).
S1P (15 mM) evoked a rapid rise in force (initial transient),
which was followed by a secondary sustained force.
(Figure 1, inset of B1). S1P-induced contraction was
concentration-dependent (Figure 1, B1 and B2). The magni-
tude of the 15 mM S1P-induced contractions was 103.62+
15.65% (initial transient force, n ¼ 6) of the contraction pro-
duced by 70 mM Kþ solution. We also tested the effect of the
same volume of vehicle (methanol) used at 30 mM S1P on the
resting and 70 mM Kþ solution-induced contraction, respect-
ively. Treatment with vehicle had no effect (data not
shown).
Figure 1 Effects of sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) on force in rabbit coronary artery. (A1 and A2) Typical recoding (A1)
and statistical evaluation (A2) showing the concentration–response curve obtained by cumulative addition of sphingosylphosphorylcholine. The inset illustrates
the effect of 5 mM sphingosylphosphorylcholine on the force. (B1 and B2) Typical recoding (B1) and statistical evaluation (B2) showing the concentration–response
curve obtained by cumulative addition of sphingosine-1-phosphate. The inset illustrates the effect of 15 mM sphingosine-1-phosphate on the force. Data are
expressed as relative percentage of 70 mM Kþ solution-induced contraction (n ¼ 6).
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3.2 Role of Ca21 influx through plasma membrane
and/or Ca21 release from sarcoplasmic reticulum
on the SPC- and S1P-induced contractions in rabbit
coronary artery
To clarify the role of Ca2þ influx through plasma membrane
in the SPC- and S1P-induced contractions in the rabbit cor-
onary artery, we tested the effect of SPC and S1P on con-
tractile force in the absence of extracellular Ca2þ. In the
absence of extracellular Ca2þ, SPC (5 mM) still evoked a
gradual and sustained contraction in rabbit coronary
artery, which reached a maximum plateau level within
20 min (Figure 2, inset of A1). As shown in Figure 2A2, the
SPC-induced contraction was concentration-dependent,
but this was shifted to the right in the absence of extracellu-
lar Ca2þ compared with the presence of extracellular Ca2þ.
The maximum response of SPC-induced contraction was
slightly decreased by the absence of extracellular Ca2þ.
The magnitude of the 5 mM SPC-induced contraction was
83.60+5.34% (n ¼ 6) of the contraction produced by
70 mM Kþ solution. In contrast, as shown in Figure 2B,
S1P-induced contraction was smaller in the absence of
extracellular Ca2þ compared with the presence of extra-
cellular Ca2þ. At the 15 mM S1P, the initial peak magnitude
of S1P-induced contraction in the absence and presence of
extracellular Ca2þ was 26.88+4.91 and 103.62+15.65%
(P, 0.05, n ¼ 6), respectively.
To determine the involvement of Ca2þ release from
sarcoplasmic reticulum (SR) in SPC- and S1P-induced con-
tractions, the effect of 20 mM CPA, a sarcoplasmic reticular
Ca2þ ATPase (SERCA) inhibitor, was examined on SPC- or
S1P-induced contractions. In the absence of extracellular
Ca2þ, SPC (5 mM)-induced contraction was partially
reduced, but not significantly, by pre-treatment of arterial
rings with 20 mM CPA. The magnitude of contraction
responses to SPC without and with CPA was 89.66+4.68
and 65.53+6.56% (n ¼ 6), respectively (Figure 3A1 and A2).
In contrast, pre-treatment of arterial rings with 20 mM CPA
significantly decreased the initial transient force induced by
S1P (15 mM). The magnitude of S1P-induced contractions in
the absence and presence of CPA was 33.52+5.29 and
16.72+4.71% (P, 0.05, n ¼ 6), respectively. However, the
secondary sustained force of S1P-induced contraction was
not affected by CPA pre-treatment (Figure 3B1 and B2).
To confirm the role of Ca2þ influx through plasma mem-
brane and/or Ca2þ release from SR in the SPC- and
S1P-induced contractions, we measured changes in intra-
cellular Ca2þ transients in single isolated coronary arterial
cells using Ca2þ-imaging techniques. As shown in Figure 4A
and B, in the presence of extracellular Ca2þ, SPC (5 mM)
barely elevated [Ca2þ]i (2.95+1.38%, n ¼ 5, relative to
percentage of 50.5 mM Kþ solution, Figure 4E), but S1P
(1 mM) significantly increased [Ca2þ]i (65.52+5.47%, n ¼
5, relative to percentage of 50.5 mM Kþ solution,
Figure 4E). In the absence of extracellular Ca2þ,
S1P-induced increase in [Ca2þ]i was significantly inhibited
(Figure 4C). The magnitude of S1P-induced increase in
[Ca2þ]i in the absence of extracellular Ca
2þ was 16.74+
2.80% (n ¼ 5) of the [Ca2þ]i produced by 50.5 mM Kþ solution
Figure 2 Effects of sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) on force in the absence of extracellular Ca2þ. (A1 and A2) Typical
recoding (A1) and statistical evaluation (A2) showing the concentration–response curve obtained by cumulative addition of sphingosylphosphorylcholine in the
absence of extracellular Ca2þ. The inset illustrates the effect of 5 mM sphingosylphosphorylcholine on the force. (B1 and B2) Typical recoding (B1) and statistical
evaluation (B2) showing the concentration–response curve obtained by cumulative addition of sphingosine-1-phosphate in the absence of extracellular Ca
2þ. The
inset illustrates the effect of 15 mM sphingosine-1-phosphate on the force. Data are expressed as relative percentage of 70 mM Kþ solution-induced contraction
(n ¼ 6). *P , 0.05 compared in the presence of extracellular Ca2þ.
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(Figure 4E). In contrast, pre-treatment of single cells with
5 mM CPA completely abolished the S1P-induced increase in
[Ca2þ]i (Figure 4D).
To investigate the nature of channel(s) involved in the
extracellular Ca2þ influx induced by S1P, we tested the
effect of nifedipine, a voltage-operated Ca2þ channel
blocker, on the S1P-induced contraction. Pre-treatment
with 1 mM nifedipine did not evoke significant changes in
S1P-induced contraction (data not shown). The effect of
S1P on the Ca2þ entry through store-operated Ca2þ channels
was assessed by evaluating the effect of SKF-96365 on the
S1P-induced contraction. Pre-treatment of arterial rings
with 10 mM SKF-96365 significantly decreased the force
induced by 15 mM S1P (data not shown).
3.3 Role of Ca21-sensitization mechanisms on the
SPC- and S1P-induced contractions in rabbit
coronary artery
To determine the role of Ca2þ-sensitization mechanisms in
the SPC- and S1P-induced contractions in the rabbit coronary
artery, we observed the effect of SPC and S1P on contractility
at a constant supra-basal but sub-maximal activating [Ca2þ]i
level using b-escin permeabilized strips. As shown in Figure 5,
SPC (5 mM) induced significant augmentation of the pCa
6.3-induced force (46.97+8.47%, n ¼ 5, relative to the per-
centage of pCa 4.5) but this SPC-induced force was abolished
by treatment of 5 mM fasudil hydrochloride, a ROCK inhibitor.
On the other hand, S1P (15 mM) induced little or no augmen-
tation of force induced by pCa 6.3.
To further determine whether RhoA/ROCK pathway-
mediated Ca2þ sensitization may play a role in the SPC-
and S1P-induced contractions, the effect of 5 mM fasudil
hydrochloride was examined on SPC- and S1P-induced
responses of intact arteries. As shown in Figure 6A1 and
A2, fasudil hydrochloride (5 mM) significantly blunted SPC
(5 mM)-induced contraction. The magnitude of contrac-
tions in response to SPC without and with fasudil hydro-
chloride was 101.04+ 9.93 and 12.50+7.90% (P , 0.05,
n ¼ 5). In contrast, pre-treatment of arterial rings with
5 mM fasudil hydrochloride had no effect on the initial
transient force induced by S1P (15 mM). The magnitude
of S1P-induced initial transient contractions in the
absence and presence of fasudil was 73.99+3.40 and
70.91+ 5.30% (n ¼ 5), respectively. However, fasudil
hydrochloride significantly inhibited the secondary sus-
tained force of S1P-induced contraction (Figure 6B1 and
B2). The magnitude of S1P-induced secondary sustained
contractions in the absence and presence of fasudil was
51.01+ 5.84 and 15.15+ 5.12% (P , 0.05, n ¼ 5),
respectively.
To determine the potential downstream effectors of SPC
and S1P, we measured MYPT1 phosphorylation in SPC- and
S1P-treated rabbit coronary arterial strips. As shown in
Figure 7, SPC (5 mM) induced a several-fold increase in
Thr696 (to 2.92+0.93-fold) and Thr853 (to 4.13+
1.55-fold) phosphorylation of MYPT1 in the rabbit coronary
artery. However, S1P did not significantly affect phosphoryl-
ation of MYPT1 either at Thr696 (to 1.19+0.56-fold) or at
Thr853 (to 1.15+0.33-fold).
Figure 3 Effect of cyclopiazonic acid (CPA) (20 mM) on the sphingosylphosphorylcholine (SPC)- (A1 and A2) and sphingosine-1-phosphate (S1P) (B1 and
B2)-induced contraction in the absence of extracellular Ca
2þ. Cyclopiazonic acid (20 mM) was present 30 min before and after application of sphingosylphosphor-
ylcholine (5 mM) or sphingosine-1-phosphate (15 mM). Data are expressed as relative percentage of 70 mM Kþ solution-induced contraction (n ¼ 6). *P , 0.05
compared with control (in the absence of cyclopiazonic acid).
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Figure 4 Effects of sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) on intracellular Ca2þ transient in isolated single-coronary artery
smooth muscle cells. (A) Ca2þ transient evoked by sphingosylphosphorylcholine (5 mM) in the presence of extracellular Ca2þ in isolated single-coronary artery
smooth muscle cells. (B and C) Ca2þ transient evoked by sphingosine-1-phosphate (1 mM) in the presence (B) and absence (C) of extracellular Ca2þ. (D) The
effect of cyclopiazonic acid (CPA) on the sphingosine-1-phosphate-induced increase in Ca2þ transient in the absence of extracellular Ca2þ. Cyclopiazonic acid
(5 mM) was present 15 min before and after the application of sphingosine-1-phosphate (1 mM). (E) The effect of the same volume of solvent, ethanol, or metha-
nol on the resting Ca2þ ratio. (F) Statistical evaluation showing the sphingosine-1-phosphate-induced increase in Ca2þ transient at the different conditions. Data
are expressed as relative percentage of 50.5 mM Kþ solution-induced response (n ¼ 5). *P, 0.05 compared with resting; **P, 0.05 compared with
sphingosine-1-phosphate only; P , 0.05 compared with sphingosine-1-phosphate under 0Ca2þþEGTA.
Figure 5 Effects of sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) on the contractility in b-escin permeabilized rabbit coronary artery.
(A and B) Typical records for sphingosylphosphorylcholine- (A) and sphingosine-1-phosphate (B)-induced force in b-escin permeabilized rabbit coronary artery.
Sphingosylphosphorylcholine or sphingosine-1-phosphate was added when pCa 6.3-induced force was stable, and fasudil hydrochloride was added after
sphingosylphosphorylcholine-induced force was stable. (C) Statistical evaluation showing the sphingosylphosphorylcholine- and sphingosine-1-phosphate-induced
changes in force at the different conditions. Data are expressed as relative percentage of pCa 4.5-induced response (n ¼ 5). *P , 0.05 compared with pCa 6.3;
**P , 0.05 compared between sphingosylphosphorylcholine and sphingosylphosphorylcholineþfasudil.
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4. Discussion
4.1 Comparison of contractile responses to SPC
and S1P
In this study, we have shown that SPC induced a
concentration-dependent and sustained contraction,
whereas S1P evoked a concentration-dependent rapid and
transient rise in force which was followed by a secondary
sustained contraction of lower magnitude. These results
are consistent with previous reports concerning SPC- or
S1P-induced contractions.12,14,15,21,27,34 However, the pat-
terns of S1P-induced contraction between the present
study and previous results show some differences.12,14,27 In
canine basilar artery, S1P also induced biphasic contrac-
tion,27 similar to our results with coronary arteries, but
most other previous results reported that S1P induced a sus-
tained contraction.12,14 These discrepancies are unlikely to
be related to the presence of an endothelium—present in
others experiments27 but absent in our experiments—but
may be related to vessel-specific and/or cell-specific
Figure 6 Effects of fasudil hydrochloride (5 mM) on the sphingosylphosphorylcholine (SPC)- (A1 and A2) and sphingosine-1-phosphate (B1 and B2)-induced con-
traction. Fasudil hydrochloride (5 mM) was present 30 min before and after the application of sphingosylphosphorylcholine (5 mM) or sphingosine-1-phosphate
(15 mM). Data are expressed as relative percentage of 70 mM Kþ solution-induced contraction (n ¼ 5). *P, 0.05 compared with control (in the absence of
fasudil).
Figure 7 Effects of sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) on phosphorylation of MYPT1. (A1 and A2) sphingosylphosphorylcholine
and sphingosine-1-phosphate induced Thr696 MYPT1 phosphorylation. (B1 and B2) sphingosylphosphorylcholine and sphingosine-1-phosphate induced Thr
853 MYPT1
phosphorylation. Thr696 phosphorylation and Thr853 phosphorylation of MYPT1 were analysed in resting and sphingosylphosphorylcholine (or
sphingosine-1-phosphate)-treated strips by western blotting using phosphorylation site-specific anti-phospho-MYPT1 antibodies. Results are representatives of
immunoblots from three independent preparations. *P, 0.05 compared with control.
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receptor expressions/coupling. Although there are many
reports concerned with SPC- and S1P-induced contractions,
the present study is the first to compare directly the pat-
terns of SPC- and S1P-induced contractions in the same cor-
onary arterial bed.
4.2 Comparison of signalling mechanisms involved
in SPC- and S1P-induced contractions
It has been shown that SPC- and S1P-induced vasoconstric-
tions are mediated by combination of Ca2þ mobilization
from IP3-sensitive store,
16,35 Ca2þ influx through L-type
Ca2þ channel36 and other Ca2þ entry mechanisms,34 and
Ca2þ sensitization of contractile protein via RhoA/ROCK
pathway.13,15,16,21–23,37–39 In the present study, to evaluate
whether increases in [Ca2þ]i contribute to the SPC- and
S1P-induced contractions, we first measured the effect of
the removal of extracellular Ca2þ and CPA on the SPC- and
S1P-induced contractions in rabbit coronary arterial rings.
SPC-induced contraction was only slightly decreased by the
absence of extracellular Ca2þ, but S1P-induced contraction
was significantly suppressed in the absence of extracellular
Ca2þ. Pre-treatment with CPA did not affect the
SPC-induced sustained contraction but significantly
decreased the initial transient force induced by S1P. Fur-
thermore, S1P, but not SPC, significantly increased [Ca2þ]i
in isolated coronary artery smooth muscle cells. In the
absence of extracellular Ca2þ, the S1P-induced increase in
[Ca2þ]i was significantly inhibited, and combined treatment
with CPA completely abolished S1P-induced increase in
[Ca2þ]i. These results suggest that S1P-induced increase in
[Ca2þ]i might be responsible for the S1P-induced contraction
consistent with the previous findings.16,20,36 However, in the
present study, the discrepancy between SPC-induced con-
traction in intact strips and changes in [Ca2þ]i in isolated
single cells still exists. In spite of SPC barely elevating
[Ca2þ]i in isolated cells, SPC-induced contraction was
slightly decreased by the absence of extracellular Ca2þ.
Therefore, a minor involvement of Ca2þ influx on the
SPC-induced contraction still remains a possibility to be
fully explored.
To investigate the role of Ca2þ-sensitization mechanisms
in the SPC- and S1P-induced contractions, we investigated
the effect of SPC and S1P on contractility at constant
[Ca2þ]. We showed that SPC induced significant augmenta-
tion of the pCa 6.3-induced force in b-escin permeabilized
strips, but S1P had little or no effect. These results
suggest that Ca2þ-sensitization mechanism may play a key
role in SPC-induced contraction, but not in S1P-induced con-
traction and are also consistent with previous findings that a
Ca2þ-sensitization mechanism is involved in SPC-induced
vasoconstriction.13,15,21
It is known that vascular contractility depends on the
20 kDa myosin light chain (MLC20) phosphorylation, which
is regulated by myosin light chain kinase (MLCK) and MLCP
activities. Phosphorylation of MLC20 is a key event in the
contraction of vascular smooth muscle and reflects the rela-
tive activities of the Ca2þ/calmodulin-dependent MLCK and
the Ca2þ-independent MLCP. MLCP is composed of three sub-
units: a catalytic subunit of type 1 phosphatase, PP1c; a tar-
geting subunit, termed myosin phosphatase target subunit,
MYPT1; and a smaller subunit, M20, of unknown function.
Phosphorylation of inhibitory sites on MYPT1, Thr696, and
Thr853 results in inhibition of PP1c activity.38,39 It is well
established that RhoA activates ROCK, which can phosphor-
ylate MYPT1 and inhibit its activity, thus increasing MLC20
phosphorylation.37
In the present study, to investigate whether RhoA/ROCK
pathway is involved in Ca2þ-sensitization mechanism, we
examined the effect of fasudil hydrochloride, ROCK inhibi-
tor, on SPC- and S1P-induced vasoconstrictions in intact
and permeabilized tissues. We showed that fasudil hydro-
chloride significantly inhibited SPC-induced contraction in
intact and permeabilized tissues. These results suggest
that the RhoA/ROCK pathway-mediated Ca2þ-sensitization
mechanism plays a major role in SPC-induced contraction.
These results are consistent with the previous findings that
RhoA/ROCK pathway is involved in SPC-induced vasocon-
striction.13,15,21 To further confirm the involvement of
RhoA/ROCK pathway-mediated Ca2þ sensitization in SPC-
and S1P-induced vasoconstrictions, we examined the
effect of SPC and S1P on the MYPT1 phosphorylation level.
SPC induced a several-fold increase in Thr696 and Thr853
phosphorylation of MYPT1 in rabbit coronary artery, but
S1P did not significantly affect phosphorylation of MYPT1
either at Thr696 or at Thr853. Taken together, our results
suggest that RhoA/ROCK pathway is activated by SPC,
resulting in the inhibition of MLCP by phosphorylation of
MYPT1.
Our results are compatible with the hypothesis that SPC
and S1P may be spasmogenic substances in coronary arteries.
However, SPC may be a better candidate than S1P because
SPC-induced contraction is evoked by the activation of
RhoA/ROCK pathway, which is known as a major mechanism
in vasospasm. In the present study, we used second branches
of left descending coronary artery. The size of this artery is
larger than that of resistance artery. Therefore, the compari-
son of SPC- and S1P-induced contractions in resistance coron-
ary arteries also requires elucidation.
S1P receptors have been identified.40 These receptors
were initially called endothelial differentiation gene (EDG)
receptors and have been renamed as S1P receptors. They
are S1P1 (EDG-1), S1P2 (EDG-5), S1P3 (EDG-3), S1P4
(EDG-6), and S1P5 (EDG-8). Because we did not elucidate
which receptor is involved in SPC- or S1P-induced contrac-
tion in the present study, the nature of the receptor(s)
involved in the SPC or S1P response still remains elucidated.
SPC can bind to EDG receptors with a potency about two
orders of magnitude lower than S1P.
In summary, our results suggest that SPC-induced contrac-
tion in rabbit descending coronary arteries shows gradual
and sustained patterns but S1P-induced contraction shows
an initial transient and then a secondary sustained
pattern. Furthermore, activation of RhoA/ROCK pathway
and phosphorylation of MYPT1 may be key mechanisms for
SPC-induced contraction, whereas elevation of [Ca2þ]i may
be a key mechanism for S1P-induced contraction.
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